Vorozole

Vorozole

Clinical data
ATC code	L02BG05 (WHO)
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Elimination half-life	8 hours
Identifiers
IUPAC name 6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
CAS Number	118949-22-7 N
PubChem CID	6918191
ChemSpider	5293402 Y
UNII	1E2S9YXV2A
KEGG	D03786 Y
ChEMBL	ChEMBL224060 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H13ClN6
Molar mass	324.768 g/mol
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4
NY (what is this?)  (verify)

WikiDoc Resources for Vorozole
Articles
Most recent articles on Vorozole Most cited articles on Vorozole Review articles on Vorozole Articles on Vorozole in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Vorozole Images of Vorozole Photos of Vorozole Podcasts & MP3s on Vorozole Videos on Vorozole
Evidence Based Medicine
Cochrane Collaboration on Vorozole Bandolier on Vorozole TRIP on Vorozole
Clinical Trials
Ongoing Trials on Vorozole at Clinical Trials.gov Trial results on Vorozole Clinical Trials on Vorozole at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Vorozole NICE Guidance on Vorozole NHS PRODIGY Guidance FDA on Vorozole CDC on Vorozole
Books
Books on Vorozole
News
Vorozole in the news Be alerted to news on Vorozole News trends on Vorozole
Commentary
Blogs on Vorozole
Definitions
Definitions of Vorozole
Patient Resources / Community
Patient resources on Vorozole Discussion groups on Vorozole Patient Handouts on Vorozole Directions to Hospitals Treating Vorozole Risk calculators and risk factors for Vorozole
Healthcare Provider Resources
Symptoms of Vorozole Causes & Risk Factors for Vorozole Diagnostic studies for Vorozole Treatment of Vorozole
Continuing Medical Education (CME)
CME Programs on Vorozole
International
Vorozole en Espanol Vorozole en Francais
Business
Vorozole in the Marketplace Patents on Vorozole
Experimental / Informatics
List of terms related to Vorozole

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

It is selective.